secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001645113-24-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure reports Q4 net loss $47.1M, full year revenue down 5%; NSCLC PMA accepted
--------------------------------------------------------------------------------

- Full year 2023 net revenues $509.3M, down 5% YoY; Q4 net revenues $133.8M, up 4% YoY.
- Q4 net loss $47.1M ($0.45 loss per share); adjusted EBITDA -$31.6M.
- Active patients 3,755 (+9% YoY); prescriptions 1,564 (+14% YoY).
- FDA accepted PMA for TTFields in NSCLC; enrollment completed in phase 3 TRIDENT trial.
- Cash, cash equivalents and short-term investments $910.6M as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/0001645113-24-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000007/nvcr-20240222.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer